News | October 11, 2024
OneSource unveils new brand identity at CPHI Milan
Aims to achieve CDMO sales of US$ 400 million by 2028
Aims to achieve CDMO sales of US$ 400 million by 2028
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
he company will focus on production of any pharmaceutical and biotechnological products
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Subscribe To Our Newsletter & Stay Updated
